Abstract

Asthma is a severe and chronic disabling disease affecting more than 300 million people world-wide. While in the past few drugs for treatment of asthma were available, new treatment options are currently emerging which appear to be highly effective in certain subgroups of patients. Accordingly there is a need for biomarkers which allow selection of patients for refined and personalized treatment strategies. Recently, serological chip tests based on micro-arrayed allergen molecules and peptides derived from the most common rhinovirus strains have been developed which may discriminate two of the most common forms of asthma, i.e., allergen- and virus-triggered asthma. In this perspective we argue that classification of asthma patients according to these common trigger factors may open new possibilities for personalized management of asthma.

Keywords

wheeze;

Data

Language: English
Year of publishing:
Typology: 1.01 - Original Scientific Article
Publisher: Elsevier Inc.
UDC: 616-097
COBISS: 2048639089 Link will open in a new window
ISSN: 1097-6825
Views: 1698
Downloads: 599
Average score: 0 (0 votes)
Metadata: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Other data

Secondary keywords: sopenje;Allergy and immunology;Diagnosis;Therapy;Asthma;Signs and symptoms, respiratory;Rhinovirus;Allergens;Microarray analysis;Precision medicine;Alergija in imunologija;Diagnostika;Terapija;Astma;Respiratorni znaki in simptomi;Rinovirus;Alergeni;Analiza mikromrež;Personalizirana medicina;
Source comment: Nasl. z nasl. zaslona; Soavtorica iz Slovenije: Mihaela Zidarn; Opis vira z dne 28. 2. 2020;
Pages: str. 1529-1534
Volume: ǂVol. ǂ145
Issue: ǂiss. ǂ6
Chronology: Jun. 2020
DOI: 10.1016/j.jaci.2020.02.001
ID: 11928336